Key Takeaways Phibro shares jumped 52.8% in a year, outperforming both the industry and S&P 500 composite indexes. PAHC's Animal Health sales rose 42% in fiscal Q3, led by 68% growth in MFAs and microbial product demand. Phibro expanded globally with a new Brazil vaccine site and Zoetis acquisition, adding 37 product lines.Phibro Animal Health (PAHC) shares have climbed 52.8% in a year, showcasing impressive momentum. The stock has outpaced the industry’s 14.3% growth and the S&P 500 composite’s 11.7% gai ...

Key Takeaways URBN, PAHC and STRT meet momentum criteria with positive trends in price and strong EPS growth. Each stock has outpaced earnings estimates, with STRT posting a 195.8% average surprise over four quarters. URBN and PAHC hold Momentum Score of A and B, respectively, signaling continued price strength.Wall Street may encounter volatility as trade tensions between the United States and China reignite. The United States blamed China for breaching a temporary trade deal, while Beijing accused Washi ...

Phibro Animal Health Corporation Financial Results Fiscal Year 2025 Third Quarter Ended March 31, 2025 Webcast and Conference Call May 8, 2025 Webcast and Conference Call May 8, 2025 U.S. toll-free +1.888.330.2022 Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or current fact included i ...